"Designing Growth Strategies is in our DNA"

Preclinical CRO Market Size, Share & COVID-19 Impact Analysis, By Type (Drug Metabolism and Pharmacokinetics (DMPK), Bioanalysis, Toxicology Studies, and Safety Services), By Application (Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders, and Others), By End-user (Pharmaceutical & Biotechnological Companies, Academic & Research Institutes, and Others), and Regional Forecast, 2023-2030

Last Updated: May 27, 2024 | Format: PDF | Report ID: FBI106939

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global preclinical CRO market size was valued at USD 6.84 billion in 2022 and is projected to grow from USD 7.79 billion in 2023 to USD 19.41 billion by 2030, exhibiting a CAGR of 13.9% during the forecast period (2023-2030). North America accounted for a market value of USD 3.42 billion in 2022. The rising focus on cost-effective and time-efficient drug development is driving the market growth.


Biotechnology and biopharmaceutical companies have increased their focus on outsourcing their R&D for new therapeutics to contract research organizations (CROs) for cost-effective and time-efficient research studies. Factors such as enhanced preclinical testing, decentralized studies, regulatory compliance, risk management, and cost reduction have been fueling the outsourcing of research studies by healthcare companies and research institutes to preclinical CROs.


Conducting preclinical studies for new drug candidates or therapies can be quite costly and time-consuming. For instance, the total R&D cost for a new medicine can range from USD 944.0 million to USD 2,826.0 million. Moreover, this cost can go higher depending on the duration and size of the study. In order to reduce this cost and accelerate research studies, drug manufacturers, especially smaller companies with limited resources, prefer outsourcing their studies to preclinical CROs.


Moreover, the increasing focus of key players on effective drug development to control the rising burden of chronic diseases such as cancer and Alzheimer’s has also been fueling market growth.


COVID-19  IMPACT


Increased Demand for Effective Treatment for the Virus Fueled the Market Growth


The sudden outbreak of COVID-19 slowed down the research activities in the early months of 2020. However, the market experienced overall significant growth in 2020 due to the increased number of preclinical studies driven by the increased demand for vaccines and therapeutics.



  • For instance, as per the World Health Organization (WHO), there were around 5,596 phase 0 trials registered in 2020, experiencing an increase of 90.6% from the prior year. 


Moreover, the market players experienced significant growth in their revenues. For instance, Laboratory Corporation of America Holdings, through its business segment Labcorp Drug Development (DD), generated revenue of USD 4,877.7 million in 2020, with a growth of 19.8% from 2019.


Furthermore, the global preclinical contract research organization (CRO) market grew significantly post-COVID-19 in 2021. This was due to the increased penetration of CROs for conducting preclinical studies. Market players experienced growth in their revenue post-COVID-19 outbreak in 2021.  For instance, Laboratory Corporation of America Holdings, through its business segment Labcorp Drug Development (DD), generated a revenue of USD 5,845.5 million in 2021, with a growth of 6.5% from 2020.


Preclinical CRO Market Trends


Increasing Penetration of CROs in Preclinical Studies Due to High Drug Development Cost


Expenditures involved in conducting preclinical studies for certain disease indications can go very high, depending upon the duration and size of the studies. The rise in average R&D expenses could be due to changes in the types of pharmaceuticals being produced or due to the number of drugs undergoing expensive research studies. R&D expenditures are high if the preclinical study success rate of biologics is low compared to the traditional small molecule pharmaceuticals.


R&D spending of private pharmaceutical companies has surged significantly in recent years. For instance, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA), pharmaceutical R&D expenditure in 2021 reached USD 43,638.3 million, which was 4.6% higher than the prior year.


Higher preclinical studies cost is one of the reasons for increased pharmaceutical R&D spending. Contract research organizations (CROs) play a crucial role in helping manufacturers save time and money by reducing trial duration. CROs help in conducting preclinical studies through their service offerings, such as toxicology studies, safety services, bioanalysis, pharmacokinetics etc.


Many pharmaceutical and biotechnological companies have started collaborating with CROs to outsource their research studies.



  • For instance, in January 2023, Charles River and Rznomics Inc., a biopharmaceutical company, partnered together to develop and manufacture RNA-based anticancer gene therapy.


Earlier research conducted by small pharmaceutical and biotechnological companies was limited due to a lack of facilities for conducting research studies in-house. Nowadays, with the emergence of CROs, outsourcing research studies by small or emerging countries has been increasing at a significant rate.


Request a Free sample to learn more about this report.


Preclinical CRO Market Growth Factors


Increasing Demand for Effective Drugs to Control the Rising Burden of Chronic Diseases has been Fueling the Market Growth


The burden of life-threatening diseases such as cancer, neurological conditions, and heart diseases has been increasing at a significant rate.



  • For instance, according to the American Cancer Society, estimates around 1.96 million new cancer cases in the U.S. in 2023. This number is equivalent to 5,370 new cancer cases every day.

  • Moreover, according to the Alzheimer's Association, around 6.0 million people are living with Alzheimer’s in the U.S. This number is expected to reach 13.0 million by 2050.


The increasing prevalence of these chronic diseases has fueled the demand for the development of effective novel therapeutics. Pharmaceutical and biotechnology companies have increased their investment in R&D for investigational new drug development.



  • For instance, in 2022, Lilly spent around USD 7,190.8 million and Vertex Pharmaceuticals spent around USD 2,540.3 million on their R&D.


The rising prevalence of chronic diseases and increasing expenditure of healthcare companies on R&D have been accelerating the demand for outsourcing research studies. Robust early-phase clinical studies play a crucial role in enhancing clinical trials success rate and to speed up the process of getting regulatory approvals. This factor has been accelerating the market growth.


Increasing Partnership and Collaboration of Pharmaceutical and Biotechnology Companies with CROs has been Accelerating the Market Growth


The increasing prevalence of chronic diseases has increased the demand for effective therapeutics. To fuel this demand, pharmaceutical and biotechnological companies have increased the outsourcing of their pharmaceutical R&D to contract research organizations.



  • For instance, in October 2021, Parexel International Corporation partnered with Kyoto University Hospital to enhance its clinical research opportunities.

  • Moreover, in February 2023, Charles River and Purespring Therapeutics partnered for the development and manufacture of gene therapy for renal diseases.


Such increased partnerships and collaboration of healthcare companies and research institutes with the CROs have been fueling the growth of this market.


RESTRAINING FACTORS


Lack of Skilled Workforce has been Hampering the Market Growth


Increasing globalization has increased the adoption of advanced technology, creating new job opportunities. Moreover, the rising industrialization has fueled the demand for advanced skills. All these factors have increased the competency in job opportunities.


The market players have been facing issues in hiring and maintaining skilled workforce, including scientists having experience in pharmaceutical, biotechnology, and medical devices businesses. Moreover, despite the growing demand for developing advanced products in the healthcare industry, there’s limited availability of skilled workforce.


For instance, as per the research study conducted by the Gatsby Foundation, by 2030, there will be a requirement of around 700,000 lab technicians in the U.K.


The limited availability of skilled workforce inhibits the efficiency of preclinical CROs, thereby limiting the market growth.


Preclinical CRO Market Segmentation Analysis


By Type Analysis


Increasing Outsourcing of R&D by Pharmaceutical Companies is Responsible for the Safety Services Segment Dominance


Based on type, the market for preclinical CRO is segmented into drug metabolism and pharmacokinetics (DMPK), bioanalysis, toxicology studies, and safety services.  


The safety services segment is expected to grow at the fastest CAGR during the forecast period. The growth of the segment is attributed to the increasing outsourcing of early-phase clinical studies by healthcare companies and academic & research institutes to preclinical CROs.


The toxicology studies segment dominated the global preclinical CRO market in 2022 and is expected to grow at a significant CAGR during the forecast period. Toxicology studies in preclinical trials are very important to understand safety exposure in human patients. Moreover, regulatory bodies such as the Food and Drug Administration (FDA) emphasize on the incorporation of experimental medicines that would represent drugs for toxicity testing in preclinical studies. All these factors are responsible for the segment’s dominance.


By Application Analysis


Increasing Demand for Effective Treatment for Cancer Fueled the Oncology Segment Growth


By application, the market for preclinical CRO is classified into neurology, infectious diseases, oncology, metabolic disorders, cardiology, and others.


The oncology segment led the market in 2022. The growth of the segment is attributed to the growing demand for effective cancer therapeutics and the increased number of research studies going on in oncology.



  • For instance, according to the World Health Organization (WHO), around 111 phase 0 clinical trials were registered in the U.S. for cancer diseases in 2021. This number was equivalent to the 32.1% of the total phase 0 clinical trials registered in the U.S. 


Furthermore, the neurology segment is expected to grow at a significant CAGR during the forecast period. The increase in the prevalence of neurology disorders has been fueling the segment’s growth.


The metabolic disorders segment is expected to grow at a substantial rate during the forecast period owing to the rising prevalence of metabolic disorders, due to which pharmaceutical companies have increased their focus on new drug discovery.


To know how our report can help streamline your business, Speak to Analyst


By End-user Analysis


Pharmaceutical and Biotechnological Companies Segment’s Dominated Due to Increasing Partnership between the Pharmaceutical Firms and CROs


The market for preclinical CRO is segmented into pharmaceutical and biotechnological companies, academic & research institutes, and others on the basis of end-user.


Pharmaceutical and biotechnological companies dominated the market in 2022 owing to the increased collaboration between pharmaceutical companies and CROs for the development of novel therapeutics.  



  • For instance, in June 2023, Charles River collaborated with Curigin, a biotechnology company, for the production of adenoviral vector production. With this partnership, Charles River is providing its expertise in CROs to Curigin for preclinical phases and clinical trials.


Moreover, the academic & research institutes segment are expected to grow at a significant CAGR during the forecast period owing to the increasing focus of these institutes on developing novel therapeutics for life-threatening diseases.


REGIONAL INSIGHTS


North America Preclinical CRO Market Size, 2022 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


Increasing Spending by Pharmaceutical Companies in North America is Responsible for the Market’s Growth in the Region


North America accounted for a major preclinical CRO market share, generating a revenue of USD 3.42 billion in 2022. The region’s growth is attributed to increased spending by pharmaceutical companies on R&D to improve their research studies, which has been fueling the market growth.


The growth of the market in Europe is attributed to the increasing prevalence of chronic diseases and the rise in the R&D spending by major biotechnology, pharmaceutical, and MedTech companies.



  • For instance, as per the report published by the European Federation of Pharmaceutical Industries and Associates in 2021, the pharmaceutical industry spent around USD 44,689.8 million in Europe. Such high spending is helping pharmaceutical companies to enhance their R&D for new therapeutics in the region.


Moreover, the market across the Asia Pacific is expected to grow with the fastest CAGR during the study period. The cost of conducting preclinical and clinical studies is comparatively cheaper in the Asia Pacific countries than in Western countries. This factor has led to increased focus by market players on conducting preclinical studies in this region, driving market growth.


The market in the rest of the world is expected to grow at a substantial CAGR during the forecast period. The increasing interest of the pharmaceutical and biotechnological companies in outsourcing their research activities in the emerging countries of Latin America and the Middle East & Africa due to cost-effectiveness is expected to fuel market growth in the region during the forecast period.


KEY INDUSTRY PLAYERS


Increasing Focus of Market Players on the Expansion of their Service offerings To Propel Market Growth


Icon plc, Syneos Health, Laboratory Corporation of America Holdings, and Charles River Laboratories are some of the significant market players as they captured a substantial global market share in 2022. The strong growth of these companies in the market is attributed to their strong focus on R&D to introduce new solutions and enhance their offerings.



  • For instance, in July 2021, Laboratory Corporation of America Holdings expanded its oncology portfolio by the acquisition of Omniseq. This acquisition upskilled the company’s offerings.


Other significant players operating in the market, such as Novotech, Medpace, and Thermo Fisher Scientific, have been focusing on expanding their presence globally to strengthen their position in the market.


LIST OF KEY COMPANIES PROFILED IN PRECLINICAL CRO MARKET:



KEY INDUSTRY DEVELOPMENTS:



  • December 2021 – Laboratory Corporation of America Holdings acquired Toxikon Corporation to strengthen its non-clinical development portfolio.

  • December 2021 – Thermo Fisher Scientific Inc. acquired Pharmaceutical Product Development, LLC. This acquisition enhanced the services provided by the company.

  • November 2021 – Icon plc expanded its Accellacare Site Network by partnering with six research sites across four countries.

  • October 2021 – Syneos Health acquired RxDataScience, a data management and Artificial Intelligence (AI) company to enhance its R&D activities with advanced technologies.

  • August 2021 –  Syneos Health announced its partnership with Aetion to provide regulatory-grade data and analytics-driven solutions to enhance drug development and patient outcomes.


REPORT COVERAGE


An Infographic Representation of Preclinical CRO Market

To get information on various segments, share your queries with us



The global preclinical CRO market report provides a detailed competitive landscape. It also includes key insights, such as top industry developments covering partnerships, mergers, and acquisitions. Additionally, it focuses on key points, such as new solution launches in the market. Furthermore, the report covers regional analysis of different segments, profiles of key market players, market trends, and the impact of COVID-19 on the market. The report consists of quantitative and qualitative insights that have contributed to the market's growth.


Report Scope & Segmentation



















































ATTRIBUTE



DETAILS



Study Period



2017-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2017-2021



Growth Rate



CAGR of 13.9% from 2023-2030



Unit



Value (USD billion)



Segmentation


 


 



By Type



  • Drug Metabolism and Pharmacokinetics (DMPK)

  • Bioanalysis

  • Toxicology Studies

  • Safety services



By Application



  • Oncology

  • Neurology

  • Cardiology

  • Infectious Diseases

  • Metabolic Disorders

  • Others



By End-user



  • Pharmaceutical & Biotechnological Companies

  • Academic & Research Institutes

  • Others



By Region



  • North America (By Type, By Application, By End-user, and By Country)


    • U.S.

    • Canada


  • Europe (By Type, By Application, By End-user, and By Country/Sub-region)


    • U.K.

    • Germany

    • France

    • Spain

    • Italy

    • Scandinavia

    • Rest of Europe


  • Asia Pacific (By Type, By Application, By End-user, and By Country/Sub-region)


    • Japan

    • China

    • Australia

    • India

    • Southeast Asia

    • Rest of Asia Pacific


  • Rest of the World (By Type, By Application, and By End-user)




Author

Jignesh Rawal ( Assistant Manager -Healthcare )

Jignesh is a skilled practitioner with over 8 years of extensive experience in market analysis an...Read More...


Frequently Asked Questions

The global preclinical CRO market size was valued at USD 6.84 billion in 2022 and is estimated to reach USD 19.41 billion by 2030.

The North America market was valued at USD 3.42 Billion in 2022. North America dominated the global market with a share of 50% in 2022.

The market is predicted to exhibit a CAGR of 13.9% during the forecast period of 2023-2030.

By application, the oncology segment dominated the market.

The rising prevalence of chronic diseases and increasing investment in R&D by pharmaceutical and biotechnological companies have been fueling the market growth.

Icon plc, Syneos Health, and Charles River Laboratories are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2017-2030
  • 2022
  • 2017-2021
  • 121

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X